ArticleAntimicrobial resistance and infection control2026
Re-evaluating microbiological testing and isolation measures for suspected MRSA carriers: insights from a retrospective study in a Dutch tertiary care center.
Article in Antimicrobial resistance and infection control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Netherlands has one of the lowest prevalences of methicillin-resistant Staphylococcus aureus (MRSA) in Europe due to its stringent Search and Destroy policy, including isolation of suspected carriers. Unexpected MRSA detection in non-isolated patients triggers contact tracing and screening of exposed patients and healthcare workers (HCWs). Given evolving epidemiology and healthcare practices, periodic re-evaluation of control measures is essential to sustain low prevalence while minimizing burden.
methodsThis retrospective study at a Dutch tertiary hospital (2022-2024) assessed (1) diagnostic accuracy and utility of rapid MRSA PCR using Copan eSwab and Xpert MRSA NxG (Cepheid, GeneXpert); (2) proportion of unexpected MRSA among newly detected carriers; (3) transmission risk after unprotected MRSA exposure; (4) implications for optimizing screening and isolation. Data were extracted from electronic patient and laboratory records. MRSA culture and PCR results (throat, nose, rectum combined) were compared and stratified by screening indication.
resultsAmong 1939 MRSA screenings, 89 (4.6%) were positive. Major screening indications were 'foreign healthcare exposure' (42.8%; 1.6% positive), 'residing in an asylum seekers' centre' (24.9%; 7.8% positive), or 'livestock contact' (14.5%; 8.6% positive). MRSA-positive household contacts had the highest MRSA test positivity (16/87; 18.4%). Compared with culture, PCR (n = 830) showed 63.9% sensitivity and 99.2% specificity, 21% of positive PCRs were false positives (7/32). Unexpected MRSA findings triggered 78 contact investigations involving 143 patients and 1550 HCWs. Nosocomial transmission occurred in 0.3% of HCWs, none in patients. Incidental MRSA was found in 0.4% of HCWs (6/1550). 30% of patients with "unexpected MRSA" lacked known risk factors; parental origin abroad was observed in 38% (exploratory analysis). "Suspected MRSA" accounted for 23% of strict isolation days.
conclusionsCurrent MRSA screening remains effective but could be optimized. Given the low transmission risk, limited PCR sensitivity, and low MRSA prevalence in high-risk groups, contact isolation instead of strict isolation may suffice while awaiting culture results in suspected carriers. A revised, risk-based approach could improve efficiency, reduce unnecessary isolation, and lower costs without compromising safety. As 30% of unexpected MRSA cases lacked established risk factors, updating screening criteria to include emerging risk factors may further strengthen detection and containment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.